Lower vs standard dose belantamab for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares a lower dose of belantamab mafodotin (a targeted antibody drug) with the standard dose, when combined with two other drugs (pomalidomide and dexamethasone) for multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if a lower dose works just as well but with fewer side effects, especially on the eyes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have multiple myeloma that has come back or not responded to treatment.
- You have had at least one prior treatment that included lenalidomide (Revlimid).
- You are generally able to care for yourself (ECOG 0-2).
- You have measurable signs of myeloma in blood, urine, or free light chains.
- You have not been treated with pomalidomide or belantamab mafodotin before.
- You do not have serious eye, heart, liver, or kidney problems, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests belantamab mafodotin in people with multiple myeloma that has come back or is not responding to several prior treatments. It may help shrink the cancer and improve disease control when standard options have already been tried.
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.